Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Gynecol Oncol. 2016 Apr;141(1):57–64. doi: 10.1016/j.ygyno.2016.01.004

Figure 3. Loss of RAD50 predicts drug sensitivity in BRCAwt OvCa cell lines.

Figure 3

(A) Drug response of Rucaparib in ovarian cancer cells with different RAD50 copy number statuses (B) Drug response of Olaprib in ovarian cancer cells with different RAD50 copy number statuses (C & D) HeyA8 cells were transfected with SiCTRL, SiRAD50-1, SiRAD50-2 and then treated with Olaparib (C) or Cisplatin (D). Cell viability was assayed by MTT assay. Curves were generated from three independent experiments. * P<0.05; ** P<0.01, two-sided Student's t test. Data represent the mean±SD from three independent experiments.